Defence Therapeutics Inc. (DTCFF)

USD 0.27

(0.0%)

Market Cap (In USD)

12.86 Million

Revenue (In USD)

-

Net Income (In USD)

-13.19 Million

Avg. Volume

289.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.2732-1.738
PE
-
EPS
-
Beta Value
1.447
ISIN
CA24463V1013
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA
Employee Count
-
Website
https://defencetherapeutics.com
Ipo Date
2021-05-18
Details
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.